Detailed View
ABUS - Arbutus Biopharma Corporation
Latest filing: 2026-03-31 | Reporting: gaap
Market Cap
865,215,232
Adj EBIT (TTM)
161,195,000
Enterprise Value
841,509,232
Last Price
4.38
Earnings Yield
19.16%
Return on Capital
59.25%
Capital
272,059,000
1Y Price Chart
Last Price: -
1Y Change: -
Company Summary
Loading summary...
| endDate | formType | fiscalYear | Revenue | OperatingIncomeLoss |
|---|---|---|---|---|
| 2026-03-31 | 10-Q | 2026 | 179,126,000 | 168,908,000 |
| 2025-12-31 | 10-K (Q4 derived) | 2025 | 1,051,000 | -5,290,000 |
| 2025-09-30 | 10-Q | 2025 | 529,000 | -8,659,000 |
| 2025-06-30 | 10-Q | 2025 | 10,739,000 | 1,488,000 |
| 2025-03-31 | 10-Q | 2025 | 1,764,000 | -25,699,000 |
| 2024-12-31 | 10-K (Q4 derived) | 2024 | 1,574,000 | -13,933,000 |
| 2024-09-30 | 10-Q | 2024 | 1,339,000 | -21,440,000 |
| 2024-06-30 | 10-Q | 2024 | 1,726,000 | -21,583,000 |
Notice something wrong?
Submit a quick report with a snapshot of the values you are seeing.